Antibiotic resistance and cagA gene correlation: A looming crisis of Helicobacter pylori

World Journal of Gastroenterology

Volumn 18, Issue 18, 2012, Pages 2245-2252

  Khan, Adnan ^a   Farooqui, Amber ^a,b   Manzoor, Hamid ^c   Akhtar, Syed Shakeel ^c   Quraishy, Muhammad Saeed ^c   Kazmi, Shahana Urooj ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c CIVIL HOSPITAL   (Pakistan)

Author keywords

Antibiotic resistance; Caga; Clarithromycin; Fluoroquinolones; Helicobacter pylori; Metronidazole; Pakistan

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; OFLOXACIN; TETRACYCLINE; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; CAGA PROTEIN, HELICOBACTER PYLORI;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CAGA GENE; CONTROLLED STUDY; DUODENUM ULCER; DYSPEPSIA; GASTRITIS; GENE FREQUENCY; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; STOMACH BIOPSY; STOMACH ULCER; BIOPSY; CHI SQUARE DISTRIBUTION; DRUG EFFECT; GENETICS; HELICOBACTER INFECTION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION; NUCLEOTIDE SEQUENCE; PAKISTAN; STATISTICAL MODEL; STOMACH;

ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BIOPSY; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LINEAR MODELS; MICROBIAL SENSITIVITY TESTS; MUTATION; PAKISTAN; STOMACH;

EID: 84866249598     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i18.2245     Document Type: Article

References (31)

1. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825
2. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20
3. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321-331
4. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781
5. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322
6. Poon SK, Lai CH, Chang CS, Lin WY, Chang YC, Wang HJ, Lin PH, Lin HJ, Wang WC. Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents. Int J Antimicrob Agents 2009; 34: 162-165
7. Shah SZA, Meron AS. Helicobacter pylori Infection in Cirrhotic Patients with Upper Gastrointestinal Bleeding. World Appl Sci J 2010; 8: 137-140
8. Abbas Z, Yakoob J, Abid S, Jafri W, Islam M, Azam Z, Hilal I. Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy. Dig Dis Sci 2009; 54: 1953-1957
9. Khokhar N. One-week therapy with omeprazole, clarithromycin and amoxicillin for eradication of Helicobacter pylori infection. J Coll Physicians Surg Pak 2002; 12: 338-340
10. Mirza IA, Mirza SH, Ali AM. Antimicrobial susceptibility pattern of H. pylori in isolates from Northern Pakistan. Int J Pathol 2007; 5: 18-20
11. Yakoob J, Abid S, Abbas Z, Jafri SN. Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area. Br J Biomed Sci 2010; 67: 197-201
12. Khan S, Rai MA, Khanani MR, Khan MN, Ali SH. HIV-1 subtype A infection in a community of intravenous drug users in Pakistan. BMC Infect Dis 2006; 6: 164
13. Chisholm SA, Owen RJ, Teare EL, Saverymuttu S. PCRbased diagnosis of Helicobacter pylori infection and realtime determination of clarithromycin resistance directly from human gastric biopsy samples. J Clin Microbiol 2001; 39: 1217-1220
14. Yamaoka Y, Osato MS, Sepulveda AR, Gutierrez O, Figura N, Kim JG, Kodama T, Kashima K, Graham DY. Molecular epidemiology of Helicobacter pylori: separation of H. pylori from East Asian and non-Asian countries. Epidemiol Infect 2000; 124: 91-96
15. CLSI. Performance standards for antimicrobial susceptibility testing. Wayne, PA.: Clinical and Laboratory Standards Institute, 2009
16. Taneike I, Nami A, O'Connor A, Fitzgerald N, Murphy P, Qasim A, O'Connor H, O'Morain C. Analysis of drug resistance and virulence-factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status? Aliment Pharmacol Ther 2009; 30: 784-790
17. Qureshi NN, Morikis D, Schiller NL. Contribution of specific amino acid changes in penicillin binding protein 1 to amoxicillin resistance in clinical Helicobacter pylori isolates. Antimicrob Agents Chemother 2011; 55: 101-109
18. O'connor A, Taneike I, Nami A, Fitzgerald N, Murphy P, Ryan B, O'connor H, Qasim A, Breslin N, O'moráin C. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol 2010; 22: 1123-1127
19. Raymond J, Lamarque D, Kalach N, Chaussade S, Burucoa C. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010; 15: 21-27
20. Momenah AM, Asghar AH. Prevalence and antibiotic resistance among helicobacter pylori clinical isolates from main Hospitals in the Western Region of Saudi Arabia. Pak J Med Sci 2008; 24: 100-103
21. Thyagarajan SP, Ray P, Das BK, Ayyagari A, Khan AA, Dharmalingam S, Rao UA, Rajasambandam P, Ramathilagam B, Bhasin D, Sharma MP, Naik SR, Habibullah CM. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. J Gastroenterol Hepatol 2003; 18: 1373-1378
22. Nahar S, Mukhopadhyay AK, Khan R, Ahmad MM, Datta S, Chattopadhyay S, Dhar SC, Sarker SA, Engstrand L, Berg DE, Nair GB, Rahman M. Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol 2004; 42: 4856-4858
23. Rimbara E, Noguchi N, Tanabe M, Kawai T, Matsumoto Y, Sasatsu M. Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001. Clin Microbiol Infect 2005; 11: 307-311
24. Ahmad N, Zakaria WR, Mohamed R. Analysis of antibiotic susceptibility patterns of Helicobacter pylori isolates from Malaysia. Helicobacter 2011; 16: 47-51
25. De Francesco V, Zullo A, Ierardi E, Giorgio F, Perna F, Hassan C, Morini S, Panella C, Vaira D. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother 2010; 65: 327-332
26. Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol 2010; 16: 5118-5121
27. Torres J, Camorlinga-Ponce M, Pérez-Pérez G, Madrazo-De la Garza A, Dehesa M, González-Valencia G, Muñoz O. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001; 39: 2677-2680
28. Toledo H, López-Solís R. Tetracycline resistance in Chilean clinical isolates of Helicobacter pylori. J Antimicrob Chemother 2010; 65: 470-473
29. Liou JM, Chang CY, Sheng WH, Wang YC, Chen MJ, Lee YC, Hung HW, Chian H, Chang SC, Wu MS, Lin JT. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin-and clarithromycin-based therapies. Antimicrob Agents Chemother 2011; 55: 1123-1129
30. Khan E, Jabeen K, Ejaz M, Siddiqui J, Shezad MF, Zafar A. Trends in antimicrobial resistance in Shigella species in Karachi, Pakistan. J Infect Dev Ctries 2009; 3: 798-802
31. Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009; 63: 1017-1024